Crizotinib price reduced by 2,400 yuan

Crizotinib (Crizotinib) is a stand-alone cancer drug containing the active ingredient crizotinib used to treat adults with non-small cell lung cancer. It can be used if the non-small cell lung cancer is "ALK positive," meaning the cancer cells contain certain changes that affect the gene responsible for a protein called ALK. It can also be used when non-small cell lung cancer is "ROS1 positive". This means that the cancer cells contain changes that affect the gene responsible for the protein ROS1.

Crizotinib may also be used to treat children and adolescents aged 6 to 18 years who have ALK-positive anaplastic large cell lymphoma (ALCL, a blood cancer) or ALK-positive inflammatory myofibroblastic tumor (IMT) that cannot be removed with surgery. IMT is usually a benign tumor that affects a type of muscle cell called myofibroblast, which plays an important role in the wound healing process.

CrizotinibThe original drug has been launched in China and is included in the scope of medical insurance, but it can only be reimbursed for patients who meet the indications. The price of each box may be around 15,000 yuan. The price after medical insurance reimbursement may need to be understood based on the local reimbursement ratio. It is unclear whether the price can be reduced by 2,400 yuan.

The Turkish original version of crizotinib currently sold overseas may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is expensive. There are also cheaper generic crizotinib drugs available overseas. The ingredients are basically similar to those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Bangladesh pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to exchange rates).